🎉 M&A multiples are live!
Check it out!

Dyne Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dyne Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Dyne Therapeutics Overview

About Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.


Founded

2017

HQ

United States of America
Employees

191

Website

dyne-tx.com

Financials

Last FY Revenue n/a

LTM EBITDA -$388M

EV

$533M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Dyne Therapeutics Financials

Dyne Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$388M.

In the most recent fiscal year, Dyne Therapeutics achieved revenue of n/a and an EBITDA of -$342M.

Dyne Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Dyne Therapeutics valuation multiples based on analyst estimates

Dyne Therapeutics P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue n/a XXX n/a XXX XXX XXX
Gross Profit n/a XXX n/a XXX XXX XXX
Gross Margin n/a XXX n/a XXX XXX XXX
EBITDA -$388M XXX -$342M XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBIT -$407M XXX -$344M XXX XXX XXX
EBIT Margin n/a XXX n/a XXX XXX XXX
Net Profit -$390M XXX -$317M XXX XXX XXX
Net Margin n/a XXX n/a XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Dyne Therapeutics Stock Performance

As of July 9, 2025, Dyne Therapeutics's stock price is $8.

Dyne Therapeutics has current market cap of $1.2B, and EV of $533M.

See Dyne Therapeutics trading valuation data

Dyne Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$533M $1.2B XXX XXX XXX XXX $-3.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Dyne Therapeutics Valuation Multiples

As of July 9, 2025, Dyne Therapeutics has market cap of $1.2B and EV of $533M.

Dyne Therapeutics's trades at n/a EV/Revenue multiple, and -1.6x EV/EBITDA.

Equity research analysts estimate Dyne Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Dyne Therapeutics has a P/E ratio of -3.0x.

See valuation multiples for Dyne Therapeutics and 12K+ public comps

Dyne Therapeutics Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $1.2B XXX $1.2B XXX XXX XXX
EV (current) $533M XXX $533M XXX XXX XXX
EV/Revenue n/a XXX n/a XXX XXX XXX
EV/EBITDA -1.4x XXX -1.6x XXX XXX XXX
EV/EBIT -1.3x XXX -1.6x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -3.0x XXX -3.7x XXX XXX XXX
EV/FCF -3.6x XXX -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Dyne Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Dyne Therapeutics Margins & Growth Rates

Dyne Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.

Dyne Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Dyne Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Dyne Therapeutics and other 12K+ public comps

Dyne Therapeutics Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth 20% XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX $1.8M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Dyne Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Dyne Therapeutics M&A and Investment Activity

Dyne Therapeutics acquired  XXX companies to date.

Last acquisition by Dyne Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Dyne Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Dyne Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Dyne Therapeutics

When was Dyne Therapeutics founded? Dyne Therapeutics was founded in 2017.
Where is Dyne Therapeutics headquartered? Dyne Therapeutics is headquartered in United States of America.
How many employees does Dyne Therapeutics have? As of today, Dyne Therapeutics has 191 employees.
Who is the CEO of Dyne Therapeutics? Dyne Therapeutics's CEO is Mr. John G. Cox.
Is Dyne Therapeutics publicy listed? Yes, Dyne Therapeutics is a public company listed on NAS.
What is the stock symbol of Dyne Therapeutics? Dyne Therapeutics trades under DYN ticker.
When did Dyne Therapeutics go public? Dyne Therapeutics went public in 2020.
Who are competitors of Dyne Therapeutics? Similar companies to Dyne Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Dyne Therapeutics? Dyne Therapeutics's current market cap is $1.2B
Is Dyne Therapeutics profitable? Yes, Dyne Therapeutics is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Dyne Therapeutics? Dyne Therapeutics's last 12 months EBITDA is -$388M.
What is the current EV/EBITDA multiple of Dyne Therapeutics? Current EBITDA multiple of Dyne Therapeutics is -1.4x.
What is the current FCF of Dyne Therapeutics? Dyne Therapeutics's last 12 months FCF is -$146M.
What is the current EV/FCF multiple of Dyne Therapeutics? Current FCF multiple of Dyne Therapeutics is -3.6x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.